Jenburkt Pharmaceuticals Limited researches and develops, manufactures, and markets pharmaceutical and healthcare products in India. The company offers products in various therapeutic areas, such as pain management, analgesic and anti-pyretics, muscle relaxants, nutraceuticals, neuropathic pain, anti-arthritic, anti-infectives, antifungals, antiulcerants/antacids, aphrodisiacs, antimalarials, anthelmintics, cough and cold, and anti- diabetics, as well as consumer products. It offers its products under the Allerzine, CartiSafe Forte, Eberjen, ECOPROT, Frendacid, Fundu, Glajen-E, GLUCOTROL, HYBRITA, Jenflam, La-Viril, LUMA, Lubtriben, Metmin, Nervega-75, Nervijen P, Nervijen, NOCAL, Numox-625, OJEN, ORNEL, Oxicojen, PANTAZOLE, PIRITEXYL, POWERDOL, Powergesic, Rabera, Topcal-M, Trapidol-D, TREGA, TRIBEN, ZENGLOBIN, ZIX, Zix-MR, Zix-PG 200/75, Zydol Suspension, and Zixa brand names. It serves its products through stockists, doctors, pharmacies, chemists, large government, semi-government institutions, missionary hospitals, and public sector enterprises. It exports its products. Jenburkt Pharmaceuticals Limited was incorporated in 1985 and is based in Mumbai, India.
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
The market has climbed 1.5% in the last 7 days, lead by the Financials sector with a gain of 2.3%. In contrast, the market has seen a decline of 4.7% over the last 12 months. Looking forward, earnings are forecast to grow by 16% annually. Market details ›